Here are complete, crisp answers from Harrison's Principles of Internal Medicine 22nd Edition (2025):
SECTION A - MCQs (Answers with Rationale)
| Q | Answer | Key Rationale (Harrison's) |
|---|
| 1 | (c) Mycoplasma pneumoniae | Most common cause of atypical (walking) pneumonia; extrapulmonary features include cold agglutinin-mediated hemolytic anemia, Stevens-Johnson syndrome, and neurologic manifestations |
| 2 | (a) Decreased FEV1/FVC ratio with bronchodilator reversibility | Asthma = obstructive pattern; FEV1/FVC <0.70, with ≥12% reversibility after bronchodilator |
| 3 | (d) Lichen Planus | Classic "5 P's": Purple, Polygonal, Planar, Pruritic, Papules on flexor wrists; Wickham's striae seen |
| 4 | (b) Erythema Chronicum Migrans | Pathognomonic of Lyme disease (Borrelia burgdorferi); expanding bull's-eye rash at tick bite site |
| 5 | (d) Pityriasis Rosea | Herald patch precedes "Christmas tree" distribution of lesions along Langer's lines on the trunk |
| 6 | (c) Auditory Hallucinations | Positive symptoms = added phenomena (hallucinations, delusions, disorganized speech). Social withdrawal, anhedonia, alogia = negative symptoms |
| 7 | (b) Lithium | Drug of choice for acute mania and long-term maintenance; also has anti-suicidal properties |
| 8 | (a) IgE | Type I hypersensitivity (anaphylactic/allergic) is mediated by IgE bound to mast cells and basophils |
| 9 | (b) Inhibition of acetylcholinesterase | Organophosphates irreversibly inhibit AChE → ACh accumulation → muscarinic effects including miosis |
| 10 | (d) Naloxone | Competitive opioid receptor antagonist; dose 0.4-2 mg IV; reverses respiratory depression, miosis, and coma |
| 11 | (b) Bamboo Spine | Ankylosing Spondylitis: ossification of annulus fibrosus + anterior longitudinal ligament → "bamboo spine" on X-ray |
| 12 | (a) Reactive Arthritis | Reiter's syndrome (urethritis + conjunctivitis + arthritis) = Reactive Arthritis; triggered by Chlamydia, Salmonella, Shigella, Campylobacter |
| 13 | (c) Trisomy 21 | Down Syndrome = three copies of chromosome 21; most commonly due to meiotic non-disjunction |
| 14 | (d) Marfan Syndrome | Autosomal dominant (fibrillin-1 gene, chromosome 15); Thalassemia = AR; PKU = AR; Cystic Fibrosis = AR |
| 15 | (b) Enteric Fever (Typhoid) | Widal test detects agglutinating antibodies against O and H antigens of Salmonella typhi |
| 16 | (c) Arsenic | Chronic arsenic poisoning: Mees' lines on nails, raindrop pigmentation (alternating hyperpigmentation/depigmentation), arsenical keratosis |
| 17 | (a) Aedes aegypti | Primary vector of Dengue, Zika, Chikungunya, Yellow Fever; breeds in stagnant clean water |
| 18 | (b) Primaquine | Radical cure of P. vivax/P. ovale (kills liver hypnozoites); must test for G6PD deficiency first |
| 19 | (b) Rifampicin, Dapsone, and Clofazimine | Paucibacillary: Rifampicin + Dapsone × 6 months. Multibacillary: Rifampicin + Dapsone + Clofazimine × 12 months |
| 20 | (a) Respiratory Failure | Elapid (cobra, krait) venom → neurotoxic → neuromuscular blockade → respiratory muscle paralysis → death |
SECTION B
Q1 - Lobar Pneumonia (35-year-old with rusty sputum, bronchial breathing)
(a) Diagnosis
Community-Acquired Pneumonia (Pneumococcal/Lobar Pneumonia) caused by Streptococcus pneumoniae. Rusty sputum, bronchial breathing, and increased vocal fremitus in a lobar distribution are classic.
(b) Pathogenesis and Pathological Stages
Pathogenesis: S. pneumoniae colonizes nasopharynx → aspirated into lungs → evades mucociliary clearance → polysaccharide capsule inhibits phagocytosis → alveolar inflammation.
4 Classic Stages (Laennec):
- Congestion (24h): Vascular engorgement, serous exudate; lung heavy and red
- Red Hepatization (2-3 days): Alveoli filled with RBCs, fibrin, neutrophils; lung firm, red, liver-like
- Grey Hepatization (4-8 days): RBC lysis; neutrophils and fibrin persist; lung grey
- Resolution (8+ days): Macrophages clear debris; normal architecture restored
(c) Investigations and CURB-65 Score
Investigations:
- CXR: lobar/segmental consolidation
- Sputum Gram stain and culture
- CBC: leukocytosis (WBC >12,000)
- Blood cultures (2 sets)
- ABG if SpO2 <94%
- Urine pneumococcal antigen
- Serum electrolytes, BUN, creatinine
CURB-65 Score (1 point each):
| C | Confusion (new onset) |
| U | Urea >7 mmol/L (BUN >19 mg/dL) |
| R | Respiratory rate ≥30/min |
| B | Blood pressure: systolic <90 or diastolic ≤60 mmHg |
| 65 | Age ≥65 years |
- Score 0-1: Outpatient
- Score 2: Consider hospitalization
- Score 3-5: Hospitalize; ICU if score 4-5
(d) Management for Hospitalized Patient
- Beta-lactam (IV amoxicillin-clavulanate or ceftriaxone 1g IV OD) PLUS macrolide (azithromycin 500 mg OD) - Harrison's preferred empiric regimen
- OR Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV/OD)
- ICU patients: beta-lactam + azithromycin or anti-pneumococcal fluoroquinolone
- Supplemental O2 to maintain SpO2 >94%
- IV fluids if hypotensive
- Antipyretics
- Thromboprophylaxis (low-molecular-weight heparin)
- Duration: 5 days (if clinically stable); de-escalate to oral when afebrile ×48h
Q2a - Falciparum Malaria: Clinical Features and Complications
Clinical Features:
- Fever (may be irregular, not classic tertian)
- Headache, myalgia, nausea, vomiting
- Splenomegaly, hepatomegaly
- Anemia, thrombocytopenia
Severe/Complications (WHO criteria):
| Complication | Mechanism |
|---|
| Cerebral malaria | Sequestration of parasitized RBCs in brain microvasculature → coma, seizures |
| Blackwater fever | Massive intravascular hemolysis → hemoglobinuria, renal failure |
| Acute Renal Failure | Hemoglobinuria + cytokine damage |
| ARDS/Pulmonary edema | Capillary leak |
| Hypoglycemia | Glucose consumption by parasites + quinine-induced hyperinsulinism |
| Algid malaria | Circulatory collapse, cold skin |
| DIC | Coagulation cascade activation |
| Hyperparasitemia | >5% parasitized RBCs = severe malaria marker |
Treatment of severe falciparum: IV Artesunate (2.4 mg/kg at 0, 12, 24h, then daily) - drug of choice.
Q2b - Leprosy: Diagnosis and WHO Classification
Diagnosis:
- Clinical: hypopigmented/erythematous skin patches with loss of sensation + thickened peripheral nerves
- Slit-skin smear: acid-fast bacilli (AFB) from ear lobe/lesion - assessed as Bacterial Index (BI)
- Skin biopsy: gold standard - granulomas with AFB
- Lepromin test: measures CMI (positive in tuberculoid, negative in lepromatous)
- PCR for M. leprae DNA
WHO Field Classification (for MDT purposes):
| Type | Skin Lesions | Nerve | Smear | Treatment |
|---|
| Paucibacillary (PB) | 1-5 lesions | ≤1 nerve | Negative | Rifampicin + Dapsone × 6 months |
| Multibacillary (MB) | >5 lesions | >1 nerve | Positive | Rifampicin + Dapsone + Clofazimine × 12 months |
Ridley-Jopling Classification: TT → BT → BB → BL → LL (tuberculoid to lepromatous spectrum)
Q2c - Management of Acute Methanol Poisoning
Mechanism: Methanol → (alcohol dehydrogenase) → Formaldehyde → Formic acid → severe metabolic acidosis + optic nerve toxicity (blindness)
Clinical features: Nausea, vomiting, headache, visual disturbance ("snowstorm vision"), high anion gap metabolic acidosis, elevated osmol gap
Management:
- ABC - airway, breathing, circulation
- Fomepizole (4-methylpyrazole) 15 mg/kg IV loading - ADH inhibitor, drug of choice (or ethanol 10% IV if fomepizole unavailable)
- Sodium bicarbonate - correct metabolic acidosis (pH <7.3)
- Folinic acid (Leucovorin) 50 mg IV q4-6h - enhances formate metabolism
- Hemodialysis - indicated if: pH <7.25, severe visual impairment, methanol level >25 mg/dL, renal failure
- Supportive care; monitor visual acuity
Q2d - HIV/AIDS: Clinical Features and WHO Clinical Staging
Clinical Features by Stage:
WHO Stage 1 (Asymptomatic):
- Asymptomatic
- Persistent generalized lymphadenopathy (PGL)
- CD4 usually >500
WHO Stage 2 (Mild):
- Weight loss <10%, minor mucocutaneous manifestations
- Recurrent oral ulcers, seborrheic dermatitis, herpes zoster, recurrent URTIs
WHO Stage 3 (Advanced):
- Weight loss >10%, chronic diarrhea >1 month
- Oral candidiasis, oral hairy leukoplakia
- Pulmonary TB, severe bacterial pneumonia
- CD4 typically <350
WHO Stage 4 (Severe/AIDS-defining):
- PCP pneumonia (Pneumocystis jirovecii)
- Cerebral toxoplasmosis, CNS cryptococcosis
- CMV retinitis
- Kaposi's sarcoma, lymphoma
- HIV wasting syndrome
- CD4 <200 defines AIDS
Antiretroviral Therapy: Start in ALL patients regardless of CD4 count. Preferred first-line: TDF + 3TC + DTG (Tenofovir + Lamivudine + Dolutegravir)
SECTION B - Q3
(a) Primary Chancre in Syphilis
- Single (occasionally multiple), painless, clean-based ulcer
- Well-demarcated, indurated (hard) edges - "cartilaginous feel"
- Appears 10-90 days (mean 3 weeks) after inoculation with Treponema pallidum
- Size: 0.5-2 cm
- Located at site of inoculation (glans, prepuce, vulva, cervix, anus)
- Associated with painless, non-tender regional lymphadenopathy (inguinal)
- Heals spontaneously in 3-6 weeks without treatment
- Highly infectious - dark-field microscopy shows spirochetes
(b) Vitamin A Deficiency - Ocular Manifestations
In order of progression (WHO grading):
- Night blindness (Nyctalopia) - earliest; rhodopsin synthesis impaired
- Conjunctival xerosis (X1A) - dry, non-wettable conjunctiva
- Bitot's spots (X1B) - foamy, cheese-like plaques on temporal conjunctiva (triangular, can't be wiped off)
- Corneal xerosis (X2) - dry, hazy cornea
- Corneal ulceration/keratomalacia (X3A/X3B) - colliquative necrosis; irreversible blindness
- Corneal scar (XS) - leucoma
Treatment: Vitamin A capsule 200,000 IU orally on days 1, 2, and 14.
(c) Koebner Phenomenon
Definition: Appearance of skin lesions characteristic of a disease at sites of trauma or injury to previously normal skin.
3 Classic Examples:
- Psoriasis - most classic; new plaques form at scratch/trauma sites
- Lichen Planus - purple papules appear along scratch lines
- Vitiligo - depigmented patches at sites of injury
Other examples: warts (viral koebnerization), molluscum contagiosum
(d) Bipolar I vs. Bipolar II Disorder
| Feature | Bipolar I | Bipolar II |
|---|
| Manic episodes | Full mania (≥7 days, hospitalization may be needed) | Absent |
| Hypomanic episodes | May occur | Present (≥4 days, not requiring hospitalization) |
| Depressive episodes | Usually present | Prominent/required for diagnosis |
| Psychosis | Can occur during mania | Does not occur in hypomania |
| Severity | More severe | Less severe overall, but depression can be disabling |
| Hospitalization | May be required for mania | Not required for hypomania |
| Key point | Mania alone = Bipolar I | No full mania ever = Bipolar II |
(e) Post-Exposure Prophylaxis (PEP) for Rabies
Wound Management (immediate, most important):
- Wash wound with soap and water for ≥15 min
- Apply povidone-iodine or 70% alcohol
Rabies Immunoglobulin (RIG): 20 IU/kg (human RIG) or 40 IU/kg (equine RIG)
- Inject as much as possible into and around the wound
- Remainder given IM at distant site
- Given only on Day 0 (only if not previously vaccinated)
Rabies Vaccine (Essen regimen - WHO recommended):
- Days 0, 3, 7, 14 (4-dose IM schedule) - for previously unvaccinated
- Previously vaccinated: Days 0 and 3 only (no RIG needed)
Category of exposure:
- Cat I (touching, feeding, licking intact skin): No PEP
- Cat II (nibbling, minor scratches): Vaccine only
- Cat III (transdermal bite, bat exposure, mucosal lick): Vaccine + RIG
SECTION C
Q1 - Ankylosing Spondylitis
(a) Diagnosis
Ankylosing Spondylitis (AS) - a seronegative spondyloarthropathy. Classic presentation: young male <45 years, insidious-onset low back pain >3 months, morning stiffness improving with exercise (not rest), anterior uveitis, reduced spinal flexion.
(b) Significance of HLA-B27
- HLA-B27 is a class I MHC molecule; present in 90-95% of AS patients (vs. 8% in general population)
- Relative risk of AS with HLA-B27 positivity: ~100x
- Mechanism: molecular mimicry between HLA-B27 and bacterial antigens (Klebsiella), misfolded protein theory, free heavy chain theory
- Not diagnostic alone - 8% of HLA-B27 positive individuals develop AS
- Also associated with other spondyloarthropathies: Reactive arthritis, psoriatic arthritis, IBD-associated arthritis
- Useful for supporting diagnosis when clinical features and X-ray are equivocal
- HLA-B27 positive children with arthritis + uveitis = high-risk group
(c) Schober's Test
Purpose: Objectively measures lumbar spinal flexion (detects reduced mobility in AS)
Technique:
- Patient stands erect; mark a point at L5 (lumbosacral junction)
- Mark a second point 10 cm above and another 5 cm below this mark (15 cm total span)
- Patient asked to bend forward maximally
- Remeasure the distance between the two outer marks
Interpretation:
- Normal: distance increases by ≥5 cm (from 15 cm to ≥20 cm)
- Abnormal (<5 cm increase): suggests reduced lumbar flexion as seen in AS
(d) Management including TNF Inhibitors
Non-pharmacological:
- Exercise, physiotherapy, hydrotherapy
- Posture training to prevent kyphosis
- Smoking cessation
Pharmacological:
NSAIDs (first-line):
- Indomethacin, diclofenac, naproxen - continuous use preferred over PRN
- If first NSAID fails, try second NSAID before escalating
Second-line - Biologics (TNF inhibitors):
- Indicated when: inadequate response to 2 NSAIDs over 4 weeks each
- Agents: Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab
- Reduce inflammation, improve function, slow radiographic progression
- Screen for latent TB before starting (with tuberculin test/IGRA)
IL-17 inhibitors (alternative biologics):
- Secukinumab, Ixekizumab - particularly effective for skin and joint disease
Surgical: Total hip replacement for advanced hip involvement; spinal osteotomy for severe kyphosis
Q2a - Neurotoxic vs. Vasculotoxic Snake Bite
| Feature | Neurotoxic (Elapid) | Vasculotoxic (Viper) |
|---|
| Snakes | Cobra, Krait, Mamba | Russell's viper, Saw-scaled viper, Pit viper |
| Mechanism | Pre-synaptic (krait): blocks ACh release; Post-synaptic (cobra): blocks nAChR | Proteases, hyaluronidase, phospholipases → local tissue destruction, coagulopathy |
| Local effects | Minimal swelling | Severe swelling, necrosis, blister formation |
| Systemic features | Ptosis (earliest sign), diplopia, dysphagia, respiratory paralysis, areflexia | Bleeding (hemotoxin): ecchymosis, hematuria, hematemesis, DIC |
| Pupils | Dilated (cobra) | Normal |
| Death cause | Respiratory failure | Hemorrhage, ARF |
| 20WBCT test | Normal | Abnormal (blood doesn't clot in 20 min) |
| Treatment | Polyvalent ASV + neostigmine (for post-synaptic) + atropine; ventilatory support | Polyvalent ASV; FFP, platelets; manage ARF with dialysis |
Anti-snake venom (ASV):
- Polyvalent ASV given IV (preferred over IM)
- Dose: 10 vials initial; repeat if no improvement in 1-2 hours
- Indications: coagulopathy, neurotoxicity, hemoglobinuria, local necrosis
Q2b - Status Asthmaticus Management (Emergency Department)
Definition: Severe asthma attack not responding to initial bronchodilator therapy.
Initial Assessment: SpO2, PEFR/FEV1, ABG, RR, use of accessory muscles, ability to speak.
Step-by-step ED Management:
-
Oxygen: 40-60% to maintain SpO2 93-95% (not high-flow routinely)
-
SABA (first-line): Salbutamol (albuterol) 2.5-5 mg nebulized q20min × 3 doses in first hour, then q1-4h; or MDI 4-8 puffs q20min
-
Ipratropium bromide: 0.5 mg nebulized q20min × 3 (add to SABA for severe attacks)
-
Systemic corticosteroids (mandatory): Prednisolone 40-60 mg oral or Hydrocortisone 100-200 mg IV; continue 5-7 days
-
IV Magnesium sulfate: 2g IV over 20 min - for severe/life-threatening attacks not responding to above (bronchosmolytics via calcium channel mechanism)
-
IV aminophylline: No longer recommended as first-line; use only if no response to above
-
Heliox (helium-oxygen mixture): Consider if failing
-
NIV/BiPAP: In impending respiratory failure
-
Intubation/Mechanical ventilation: Last resort; aim for permissive hypercapnia, low PEEP
Discharge criteria: PEFR >75% predicted, SpO2 >94% on room air, sustained for 1 hour
Q2c - Scleroderma: Clinical Manifestations and CREST Syndrome
Two Main Forms:
- Diffuse cutaneous SSc (dcSSc): Rapid skin involvement proximally + internal organs
- Limited cutaneous SSc (lcSSc): Skin confined to distal extremities/face = CREST syndrome
CREST Syndrome (lcSSc):
| Letter | Feature | Detail |
|---|
| C | Calcinosis cutis | Calcium deposits in skin/soft tissues, especially fingers |
| R | Raynaud's phenomenon | Episodic digital vasospasm (white → blue → red with cold/stress) |
| E | Esophageal dysmotility | Dysphagia, GERD; lower 2/3 of esophagus affected |
| S | Sclerodactyly | Tight, shiny skin of fingers; "sausage fingers" |
| T | Telangiectasia | Dilated capillaries on face, lips, hands |
Anti-centromere antibody is the hallmark of lcSSc/CREST (>90% sensitive).
Other systemic features: Pulmonary arterial hypertension (leading cause of death in lcSSc), interstitial lung disease, renal crisis (in dcSSc), Sjogren's overlap.
Q2d - Genetic Counseling: Ethical Considerations and Steps
Steps:
- Referral and indication - family history, advanced maternal age, abnormal prenatal screening
- Information gathering - 3-generation pedigree, medical records
- Risk estimation - calculate recurrence risk using Mendelian principles
- Education - explain disease, inheritance pattern, variability, penetrance
- Discussion of options - prenatal diagnosis (amniocentesis, CVS, FISH/microarray), preimplantation genetic diagnosis, adoption, childlessness
- Decision support (non-directive counseling)
- Follow-up - psychological support, referral to support groups
Ethical Principles:
- Autonomy: Non-directive counseling; patient decides freely without coercion
- Beneficence: Provide accurate information for informed decisions
- Non-maleficence: Avoid unnecessary anxiety; disclose information responsibly
- Confidentiality: Genetic information is private; duty to warn at-risk relatives (conflict)
- Justice: Equal access to genetic services
- Informed consent: Voluntary, capacity-based, with full disclosure
- Disclosure to third parties (insurers, employers) is generally prohibited
SECTION C - Q3
(a) Laboratory Diagnosis of Kala-azar (Visceral Leishmaniasis)
-
Definitive: Demonstration of Leishmania donovani (LD bodies/amastigotes)
- Splenic aspirate - most sensitive (>95%) but risky
- Bone marrow aspirate - safer, 70-80% sensitive
- Liver biopsy, lymph node aspirate
-
Serological (used in endemic areas):
- rK39 immunochromatographic test (ICT) - rapid, highly sensitive and specific; point-of-care test of choice
- DAT (Direct Agglutination Test)
- ELISA for anti-leishmanial antibodies
-
Molecular: PCR - highly sensitive, not routine
-
Blood: CBC shows pancytopenia (anemia, leucopenia, thrombocytopenia), elevated ESR, hypergammaglobulinemia, hypoalbuminemia
(b) Anaphylaxis Management - Drug and Dose
Epinephrine (Adrenaline) = cornerstone - give FIRST and immediately
| Drug | Dose | Route | Timing |
|---|
| Epinephrine | 0.3-0.5 mg (adult); 0.01 mg/kg in children (max 0.5mg) of 1:1000 solution | IM (anterolateral thigh) | Immediately |
| Oxygen | 100%, 15 L/min via non-rebreather mask | Inhalation | Immediately |
| IV Fluids | 1-2 L normal saline bolus | IV | If hypotensive |
| Diphenhydramine (H1 blocker) | 25-50 mg IV/IM | IV/IM | After epi |
| Ranitidine/Famotidine (H2 blocker) | 50 mg IV | IV | After epi |
| Hydrocortisone | 200 mg IV | IV | After epi (prevents biphasic) |
| Salbutamol nebulization | 2.5-5 mg | Inhaled | If bronchospasm |
Biphasic anaphylaxis (second reaction 8-72h later): observe for minimum 6 hours before discharge.
(c) Obsessive-Compulsive Disorder (OCD) - Clinical Features
Obsessions (intrusive, unwanted, ego-dystonic thoughts/images/urges):
- Contamination (dirt, germs)
- Harm (fear of hurting self/others)
- Symmetry, exactness
- Religious/sexual thoughts
Compulsions (repetitive behaviors/mental acts to neutralize obsessions):
- Washing/cleaning (most common)
- Checking (locks, appliances)
- Counting, arranging
- Hoarding
Diagnostic criteria (DSM-5):
- Obsessions and/or compulsions that are time-consuming (>1h/day) and cause significant distress/impairment
- Ego-dystonic (recognized as excessive/unreasonable)
- Not attributable to substances or medical condition
Y-BOCS (Yale-Brown) scale used to assess severity.
Treatment: First-line: SSRIs (fluoxetine, fluvoxamine, sertraline) + CBT with Exposure and Response Prevention (ERP)
(d) Dermatological Features of Scabies and the Burrow
Causative agent: Sarcoptes scabiei var. hominis (mite)
Burrow:
- Pathognomonic of scabies
- A tortuous, grayish-white or skin-colored linear track (5-15 mm long)
- Created by the female mite tunneling into stratum corneum to lay eggs
- Found characteristically in: finger webs (earliest and most common), flexor wrists, genitalia, buttocks, areola, umbilicus
- Dermoscopy: shows "delta-wing jet" sign (mite at end of burrow)
Other features:
- Intense pruritus (worse at night - hallmark)
- Papules, vesicles, excoriations from scratching
- Burrows are pathognomonic
- Secondary bacterial infection (impetigo)
- Norwegian (crusted) scabies: hyperkeratotic plaques; thousands of mites; in immunocompromised
Treatment: Permethrin 5% cream (drug of choice) - apply to entire body from neck down, wash off after 8-12 hours; repeat after 1 week. Oral ivermectin 200 mcg/kg alternative.
(e) Difference between Delirium and Dementia
| Feature | Delirium | Dementia |
|---|
| Onset | Acute (hours to days) | Insidious (months to years) |
| Course | Fluctuating, worse at night | Progressive, gradually worsening |
| Consciousness | Impaired (clouded) | Clear until late stages |
| Attention | Markedly impaired | Relatively preserved early |
| Orientation | Disoriented | Preserved early |
| Memory | Short-term impaired acutely | Short-term first, then long-term |
| Sleep-wake cycle | Severely disrupted | Mildly disrupted |
| Hallucinations | Common (visual > auditory) | Less common (visual in LBD) |
| Reversibility | Usually reversible (treat cause) | Irreversible (progressive) |
| EEG | Diffuse slowing | Normal early (except prion disease) |
| Duration | Days to weeks | Years |
| Common causes | Infection, drugs, metabolic, post-op | Alzheimer's, vascular, LBD, FTD |
| Treatment | Treat underlying cause; haloperidol for agitation | Cholinesterase inhibitors (donepezil), memantine |
Key distinction: Delirium = acute, fluctuating, impaired consciousness; Dementia = chronic, progressive, clear consciousness until late.
All answers based on Harrison's Principles of Internal Medicine, 22nd Edition (2025, McGraw Hill).